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Immune responses directed against viral capsid pro-
teins constitute a main safety concern in the use of 
adeno-associated virus (AAV) as gene transfer vectors in 
humans. Pharmacological immunosuppression has been 
proposed as a solution to the problem; however, the 
approach suffers from several potential limitations. Using 
MHC class II epitopes initially identified within human 
IgG, named Tregitopes, we showed that it is possible to 
modulate CD8+ T cell responses to several viral antigens 
in vitro. We showed that incubation of peripheral blood 
mononuclear cells with these epitopes triggers prolifera-
tion of CD4+CD25+FoxP3+ T cells that suppress killing of 
target cells loaded with MHC class I antigens in an anti-
gen-specific fashion, through a mechanism that seems 
to require cell-to-cell contact. Expression of a construct 
encoding for the AAV capsid structural protein fused to 
Tregitopes resulted in reduction of CD8+ T cell reactivity 
against the AAV capsid following immunization with an 
adenoviral vector expressing capsid. This was accompa-
nied by an increase in frequency of CD4+CD25+FoxP3+ 
T cells in spleens and lower levels of inflammatory infil-
trates in injected tissues. This proof-of-concept study 
demonstrates modulation of CD8+ T cell reactivity to an 
antigen using regulatory T cell epitopes is possible.
Received 22 December 2012; accepted 8 July 2013; advance online  
publication 13 August 2013. doi:10.1038/mt.2013.166
INTRODUCTION
Clinical gene therapy has made considerable progress over the 
past several years. Despite the recently reported successful clinical 
trial results using adeno-associated virus (AAV) vectors,1 the most 
commonly used vector for in vivo gene transfer, host immune 
responses directed against the AAV capsid remain a major obsta-
cle to achieving long-term correction of disease phenotype.2 A 
capsid-specific CD8+ T cell response was initially identified as the 
cause of short-lived transgene expression in the first clinical trial 
in which an AAV2 vector expressing coagulation factor IX (FIX) 
was introduced into the liver of severe hemophilia B subjects.3 In 
this trial, upon AAV gene transfer to liver, two subjects developed 
transient elevation of liver enzymes consequent to what appeared 
to be the immune rejection of transduced hepatocytes mediated 
by capsid-specific CD8+ T cells.4 A similar set of observations 
was recently made in the context of a clinical trial of hepatic gene 
transfer for FIX with an AAV8 vector.5 Results from these studies 
suggest that AAV vector administration in humans results in acti-
vation of capsid-specific CD8+ T cells in a vector dose-dependent 
fashion, with loss of transgene expression and increase in liver 
enzymes occurring above a certain vector dose threshold.
AAV vectors are nonreplicating recombinant viruses carrying 
a single-stranded DNA genome devoid of viral coding sequence; 
this genome is contained in a protein capsid comprising three 
structural proteins, VP1, VP2, and VP3.6 Upon infection, the viral 
vector capsid is present within a target cell for a defined period of 
time and is degraded through the proteasome pathway,7–9 leading 
to MHC class I (MHC I) presentation of AAV capsid epitopes, 
which ultimately flags transduced cells for destruction by capsid-
specific CD8+ T cells.7,8 Humans are naturally exposed to AAV, 
and develop both humoral and cellular immunity to the virus 
early in life.10–12 Whereas anti-AAV antibodies can completely 
block vector transduction, particularly when the vector is deliv-
ered through the bloodstream,3,13 loss of therapeutic transgene 
expression is believed to be related to the concomitant presenta-
tion of capsid antigen and activation of capsid-specific CD8+ T 
cells, resulting in clearance of AAV vector-transduced cells.3–5,14
Immune suppression can be used to induce tolerance in a vari-
ety of settings.15 In the most recent AAV8-FIX trial, capsid T cell 
responses were controlled with the administration of a short course 
of high-dose oral prednisolone;5 however the safety and efficacy of 
this intervention at higher vector doses, such as the doses required 
to achieve therapeutic efficacy in diseases like hemophilia A or 
muscular dystrophy, remains unknown. Additional concerns over 
the risks associated with the use of immunosuppression, as well 
as the fact that administration of steroids in certain subsets of 
patients is not recommended, have prompted the exploration of 
alternative strategies for the modulation of capsid T cell responses.
Regulatory T cell (Treg)-mediated immunomodulation has 
been explored as a therapeutic strategy in transplantation16 and 
autoimmunity.17 Tregs play a central role in the maintenance of 
peripheral tolerance and the control of immune responses. Tregs 
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Modulation of CD8+ T cell responses to AAV vectors
have been shown to downregulate effector responses via a variety 
of mechanisms, which include the consumption of IL-2, secretion 
of suppressor cytokines, interference of antigen-presenting cell-
mediated activation of effector T cells (Teff), the cytolysis of Teff, 
or direct cell-cell interaction mediated by surface receptor(s) at 
the surface of Treg and Teff.18 Whereas in some cases, the interac-
tion between Treg and Teff results in the death or cell cycle arrest 
of Teff, in some cases, it results in anergy, a state of unresponsive-
ness that can be reversed by removing Tregs.19
De Groot and colleagues first described the use of MHC class 
II (MHC II) epitopes located in the Fc region of IgG to modu-
late immunity.20 Coadministration of these regulatory T cell epi-
topes (Tregitopes) with immunogenic antigen reduces immune 
response in vitro and in vivo.21–24 In particular, Tregitopes have 
been shown to downregulate CD4+ T cell responses in the setting 
of common immunogens20 and in models of autoimmune dis-
eases such as experimental colitis.22 The postulated mechanism 
of action of Tregitopes involves the presentation of the peptides 
onto MHC II by antigen-presenting cells, resulting in early secre-
tion of IL-10 and promoting proliferation of Tregs. However, no 
study has been published so far on the effect of Tregitopes on 
CD8+ T cell responses; similarly, insights on the mechanism(s) 
of suppression of Teff responses by Tregitope-induced Tregs are 
still lacking.
Here, we assessed the potential of these peptides as modula-
tors of capsid-specific CD8+ T cell immunity and provide new 
insight as to their mechanism of action. In vitro experiments using 
human cells show that co-incubation of Tregitopes with AAV-
derived epitopes completely blunts capsid-specific CD8+ T cell 
responses and results in robust expansion of CD4+CD25+FoxP3+ 
T cells. Additional experiments suggest that Tregitopes expand 
antigen-specific Tregs, and that these peptides can be used to 
modulate Th1 responses directed against several antigens in the 
context of multiple MHC I alleles. Finally, expression of Tregitopes 
in vivo also decreases CD8+ T cell responses directed against the 
AAV capsid, generally reducing AAV capsid immunogenicity. 
Therefore, our work provides proof of concept for an alternative 
strategy to modulate Th1-driven immunity to AAV and possibly 
other antigens.
RESULTS
IgG-derived MHC II epitopes (Tregitopes) modulate 
AAV capsid-driven CD8+ T cell responses in vitro
To test the ability of IgG-derived MHC II epitopes (Tregitopes) 
to modulate AAV capsid-directed T cell responses, we used an in 
vitro experimental model previously described (Supplementary 
Figure S1).7,8 Briefly, human peripheral blood mononuclear 
cells (PBMCs) were restimulated in vitro with AAV capsid-
derived MHC I epitopes and Tregitopes or control peptides in 
the presence of IL-2 before using them as effectors (Teff) in a 
CTL assay against HLA-matched peptide-loaded or AAV-
transduced targets. Restimulation of Teff in the presence of 
Tregitope 167 (hTreg167), but not in the presence of three dif-
ferent scrambled versions of the same peptide, resulted in an 
almost complete loss of CTL activity against HLA-matched 
targets loaded with the HLA-B*0702 epitope VPQYGYLTL 
from AAV (Figure 1a). In this in vitro experimental system, 
we tested PBMCs from different donors with various MHC II 
haplotypes, showing a slight but not statistically significant (P = 
0.1873, linear regression), correlation between the affinity of 
Tregitopes for one subject’s MHC II alleles (iTEM score)25 
and the inhibition of Teff responses (Supplementary Figure 
S2). Then, we tested whether Tregitope modulation of CTL 
responses was also effective in the context of MHC I antigens 
naturally processed and presented via the proteasome path-
way by transducing HLA-B*0702 targets with AAV vectors at 
increasing multiplicity of infections, showing effective inhibi-
tion of CTL activity (Figure 1b). Restimulation of PBMCs in the 
presence of hTreg167 resulted in a profound downregulation of 
markers of T cell activation and effector functions (Figure 1c). 
Figure 1 IgG-derived MHC class II epitopes (Tregitopes) mediate suppression of T cell responses in vitro. (a) CTL assay in which target cells 
were loaded with the AAV-derived MHC I epitope VPQYGYLTL (HLA-B*0702-restricted) at increasing concentrations and then incubated with HLA-
matched Teff cells. Effectors were derived from HLA-B*0702 PBMC expanded in vitro against the same MHC I epitope alone (AAV, dashed line), or with 
hTreg167 (AAV+hTreg167, black line), or with three different scrambled versions of hTreg167 (Scramble 1, Scramble 2, and Scramble 3, grey lines). 
Teff:target ratio 10:1. Results are expressed as % cytotoxicity compared with a maximum cytotoxicity (cells treated with 10% SDS) after background 
subtraction. (b) CTL assay in which target cells were transduced with an AAV vector at increasing multiplicity of infections (MOIs) and then incubated 
with HLA-matched Teff cells restimulated with the AAV capsid MHC I peptide VPQYGYLTL alone (dashed line), or together with hTreg167 (black line). 
MOI, multiplicity of infection. Teff:target ratio 10:1. (c) Flow cytometry analysis of CD8+ T cell responses to the AAV MHC I epitope VPQYGYLTL. 
PBMC were restimulated in vitro in the presence of the AAV MHC I peptide VPQYGYLTL alone (AAV) or with hTreg167 (AAV+hTreg167) and then 
washed and incubated with the VPQYGYLTL peptide and stained for markers of T cell effector functions. Results are expressed as fold increase over 
non-restimulated PBMC incubated with the MHC I peptide VPQYGYLTL. For the analysis of flow cytometry data, after live/dead exclusion, cells were 
gated on lymphocytes, CD3+ T cells, and CD8+ T cells were then analyzed for IFN-γ, IL-2, TNF-α. SEB, Streptococcal enterotoxin B. Experiments 
shown were repeated at least twice. Error bars represent SEM. MFI, mean fluorescence intensity.
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Inhibition of Teff responses upon restimulation in the presence 
of hTreg167 was achieved with MHC I peptide epitopes derived 
from several additional HLA-B*0702-restricted viral antigens 
(Figure 2a–2d) but also with MHC I epitopes with different 
HLA restrictions (Figure 2e) and with hTreg289 (Figure 2f), a 
peptide with a different MHC II binding profile that was also 
derived from the Fc portion of human IgG.20 Suppression of CTL 
responses with hTreg289 was less effective than with hTreg167, 
which reflects the HLA haplotype of the donor (DRB1*0701 and 
DRB1*1501) and the fact that hTreg289 is predicted to bind only 
to DRB1*0701, while hTreg167 binds to both alleles.20 PBMCs 
labeled with CFSE prior to in vitro restimulation with AAV cap-
sid epitopes showed that in the presence or absence of hTreg167, 
both CD4+ and CD8+ T cells proliferate (Supplementary 
Figure S3); however, CD8+ T cells restimulated in the presence 
of Tregitopes exhibited lower levels of expression of the activa-
tion marker CD25 (Figure 3a,b), while there was an increase 
in the frequency of CD25+CD4+ T cells (vide infra). ELISA 
assay on conditioned media from PBMC cultured in the pres-
ence of Tregitopes showed the presence of lower levels of IL-2 
(Supplementary Figure S4, P = 0.0005, two-way ANOVA) and 
increased levels of IL-10 (Supplementary Figure S4, P = 0.0298, 
two-way ANOVA). No additional cytokine or chemokine ana-
lytes were changed, when measured by multiplex analysis of the 
conditioned media collected at  multiple time points during the 
PBMC restimulation (not shown).
These results indicate that Tregitopes added in restimula-
tion cultures efficiently modulate CD8+ T cell responses directed 
against a variety of HLA class I-restricted viral epitopes in vitro.
Restimulation of PBMCs in vitro with Tregitopes 
expands suppressive CD4+CD25+ T cells
We then looked at the expansion of CD4+CD25+ T cells in 
restimulation cultures containing AAV MHC I peptide epit-
ope only or in cultures containing Tregitopes. A population 
of CD4+CD25+ T cells was preferentially expanded when 
Tregitopes were added to the cultures (Figure 3a,b). These cells 
expressed FoxP3 (Figure  3c). Additional immunophenotyping 
of these CD4+CD25+ T cells showed that these cells were mostly 
CD127neg and expressed CTLA4 (not shown). Using negative bead 
selection, we isolated untouched CD4+ T cells (Tsupp) and used 
them in a suppression assay; these cells showed dose-dependent 
suppressor activity, with a dramatic reduction of CTL activity at a 
Tsupp:Teff cell ratio of 1:1 (Figure 3d). Magnetic bead depletion 
of the CD25+ cell fraction from PBMCs prior to in vitro restim-
ulation resulted in the loss of modulatory activity of Tregitopes 
(Figure 3e), suggesting that Tregitopes exert their functions via a 
pool of existing T cells present in peripheral blood.
Figure 2 Tregitopes can modulate CTL responses directed against several antigens and in the context of different HLA alleles. (a–d) Teff 
specific for Epstein-Barr virus (EBV), cytomegalovirus (CMV), hepatitis C virus (HCV), or influenza virus (Flu) were obtained following the protocol 
outlined in Figure S1. All MHC I epitopes were HLA-B*0702-restricted. Teff were used in the CTL assay at a Teff:target ratio of 1:10. Targets were 
peptide loaded with increasing concentrations of the relevant peptide. Results are expressed as % cytotoxicity compared to a max cytotoxicity (cells 
treated with 10% SDS) after background subtraction. Dashed line, Teff expanded from PBMC restimulated in vitro with indicated viral peptide only; 
Black line, Teff expanded in vitro with indicated viral peptide and hTreg167. (e) CTL assay in which Tregitope efficacy was tested against the AAV 
HLA-A*0101 restricted MHC I epitope SADNNNSEY. HLA-matched Teff were used in the CTL assay at a Teff:target ratio of 1:10. Targets were peptide 
loaded with increasing concentrations of the relevant peptide. Results are expressed as % cytotoxicity compared to a max cytotoxicity (cells treated 
with 10% SDS) after background subtraction. Dashed line, effectors obtained by restimulating PBMC in vitro with the SADNNNSEY epitope only; 
Black line, restimulation of PBMC was performed with the SADNNNSEY epitope from AAV and hTreg167. (f) CTL assay in which targets were loaded 
with the HLA-B*0702 epitope VPQYGYLTL from AAV. Teff were either obtained restimulating PBMC with the same AAV peptide only (AAV), or with 
the AAV peptide and Tregitope 167 (AAV+hTreg167), or with the AAV peptide and Tregitope 289 (AAV+hTreg289). Teff were used in the CTL assay at 
a Teff:target ratio of 1:10. Targets were peptide loaded with increasing concentrations of the relevant peptide. Results are expressed as % cytotoxicity 
compared to a max cytotoxicity (cells treated with 10% SDS) after background subtraction. Experiments shown were repeated at least twice. Error 
bars represent SEM.
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These results suggest that restimulation of PBMCs in 
vitro in the presence of Tregitopes expands a pool of natural 
CD4+CD25+FoxP3+ T cells with suppressive functions.
Tregitope-mediated modulation of CTL responses 
in vitro is contact dependent and associated with 
anergy of effector T cells
To investigate the mechanism(s) of action of Tregitopes in vitro, 
we carried out two experiments. In the first experiment, we tested 
whether cell-to-cell contact was a requirement for CTL inhibi-
tion. For this purpose, PBMCs were depleted of CD4+ or CD8+ 
T cells, and the CD4+CD8neg and the CD4negCD8+ fractions were 
separated into the two different compartments of a transwell sys-
tem before restimulation in vitro (Figure 4a). When unfraction-
ated PBMCs were cultured in both chambers of the transwell, 
AAV restimulation led to efficient killing of AAV peptide-loaded 
targets, whereas AAV+hTreg167 resulted in the inhibition of 
CTL activity as expected (Figure 4a). When CD4+CD8neg and 
CD4negCD8+ fractions of PBMCs were cultured in different cham-
bers of the transwell, killing of target was efficient whether or not 
Tregitope was present for the restimulation. Suppression of CTL 
killing was only observed when Teff were restimulated with both 
AAV and hTreg167 (Figure 4a) and located in the same cham-
ber, suggesting that contact between CD4+ and CD8+ T cells is 
needed to achieve suppression of CTL responses in vitro.
We then restimulated PBMCs in the presence of Tregitopes, 
AAV MHC I peptide, and IL-2 (10 ng/ml) for 14 days (two 
rounds of restimulation) and then depleted CD4+ T cells. 
Following depletion, we either used the CD4negCD8+ T cell frac-
tion in a CTL assay or incubated the cells with IL-2 (10 ng/ml) 
overnight before using them as source of effectors in a CTL assay. 
Immediately after removal of CD4+ T cells, CD4negCD8+ T cells 
were unable to kill the AAV peptide-loaded target (Figure 4b, 
CD4neg); however, a 24-hour incubation with IL-2 resulted in res-
toration of CTL activity to levels undistinguishable from those 
achieved with PBMCs restimulated with AAV MHC I epitopes 
only (Figure 4b, CD4neg + IL-2), suggesting that CD8+ T cells 
expanded in the presence of Tregitopes become anergic, possi-
bly due to lack of costimulatory signals, and that IL-2 can restore 
their killing capacity.
Figure 3 In vitro restimulation of PBMC with Tregitopes results in the expansion of a population of suppressive CD4+CD25+ T cells. Flow 
cytometry plots of PBMC restimulated in vitro with the AAV MHC I epitope VPQYGYLTL alone (AAV) (a) or with Tregitope 167 (AAV+hTreg167) 
(b). Cells were gated on lymphocytes after live/dead exclusion, CD3+ T cells, and CD4+CD8- and CD4-CD8+ T cells were analyzed for CD25+. 
(c) Histogram plot showing FoxP3 expression on CD4+CD25+ T cells restimulated with AAV-only from (a) or AAV+hTreg167 from (b); the isotype 
control is shown in red. Mean fluorescent intensity (MFI) is indicated in the figure legend. (d) Suppression experiments in which CD4+ T cells (Tsupp) 
negatively isolated from PBMC restimulated in vitro with AAV+hTreg167 (blue line) or with AAV only (green line) were mixed at defined ratios with 
CD8+ Teff negatively isolated from PBMC restimulated in vitro with the AAV only. (e) CTL assay in which Teff were derived from PBMC restimulated 
in vitro with AAV alone (AAV) or with Tregitope 167 (AAV+hTreg167). Alternatively, PBMC were depleted of CD25+ T cells prior to AAV+hTreg167 
restimulation (AAV+hTreg167 [CD25neg]). Teff:target ratio 10:1. Results are expressed as % cytotoxicity compared to a max cytotoxicity (cells treated 
with 10% SDS) after background subtraction. Experiments shown were repeated at least twice. Error bars represent SEM.
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Modulation of CTL responses in vitro is antigen 
specific
To test antigen specificity of modulation of CTL responses by 
Tregitopes, we performed the following experiment: PBMCs were 
restimulated in vitro in the presence of MHC I epitopes derived 
from AAV or EBV. Parallel cultures were established from the 
same PBMC donor in which cells were restimulated with the same 
AAV or EBV MHC I epitopes in the presence of hTreg167. At the 
end of the restimulation (14 days), CD4+ T cells (AAV-hTreg167 
CD4+ or EBV-hTreg167 CD4+, respectively) were isolated by neg-
ative magnetic bead selection, and untouched cells were mixed 
with AAV or EBV Teff at a 1:1 ratio. As outlined in Figure 5a, 
AAV-hTreg167 CD4+ efficiently suppressed AAV Teff, whereas 
EBV-hTreg167 CD4+ did not. Further confirming antigen speci-
ficity, we found that AAV-hTreg167 CD4+ did not suppress EBV 
Teff, while EBV-hTreg167 CD4+ did (Figure 5b). These results 
suggest that the in vitro inhibition of Teff responses mediated by 
Tregitopes is antigen specific.
We further investigated the antigen specificity of Tregitope-
mediated modulation by restimulating PBMCs with the HLA-
B*0702-restricted AAV epitope VPQYGYLTL and hTreg167. 
From these cultures, CD4+ T cells isolated by negative selection 
were incubated with increasing amounts of soluble human T cell 
receptor (TCR) monomers specific for the HLA-B*0702 peptide 
VPQYGYLTL8 to block access to MHC I:VPQYGYLTL com-
plexes at the surface of the CD4+ T cells. After 1 hour at room 
temperature, cells were washed twice, mixed at a 1:1 ratio with 
AAV only-restimulated Teff, and used in a CTL assay against tar-
get cells loaded with the same VPQYGYLTL peptide. Incubation 
of Tregitope-expanded CD4+ T cells with the soluble TCR mono-
mers resulted in dose-dependent elimination of their suppres-
sor activity (Figure 5c). As a control, Teff derived from PBMCs 
restimulated with AAV peptide and no hTreg167 were used, 
resulting in efficient killing of targets (Figure 5c, AAV only). As 
a second control, Teff restimulated with AAV peptide only were 
mixed 1:1 with CD4+ T cells isolated from PBMCs restimulated 
with hTreg167 and no AAV peptide; efficient lysis of targets was 
also observed in this case, indicating that Tregitopes alone with-
out MHC I epitopes do not modulate CD8+ T cell responses. 
Finally, a third control in the experiment consisted of the direct 
addition of TCR monomers to the CTL assay in which AAV-only 
effectors were used. As previously described,8 this resulted in the 
inhibition of killing of target cells due to the blockage of MHC 
I by the soluble TCR monomers. These results suggest that the 
antigen-specific suppressive activity of Tregitope-expanded sup-
pressor cells is mediated by the presence of antigen-specific MHC 
Figure 4 Suppression of CTL responses to the AAV capsid in vitro mediated by Tregitopes is contact mediated and results in anergy of effec-
tor cell. (a) Transwell experiment outline. Cells were placed in a transwell chamber in which the upper and lower chambers were separated by a per-
meable membrane (drawing). The table shows the different conditions tested in the transwell; in each of the transwell chambers untouched PBMC or 
PBMC depleted of CD4+ (CD4negCD8+) or CD8+ (CD4+CD8neg) T cells were plated and restimulated with either AAV-only or AAV+hTreg167 peptides. 
After restimulation, PBMC or CD4negCD8+ cells were harvested from the transwell and used in a CTL assay against target cells loaded with the AAV-
derived MHC I epitope VPYGYLTL at a Teff:target ratio 10:1. Results are expressed as % cytotoxicity compared to a max cytotoxicity (cells treated with 
10% SDS) after background subtraction. (b) CTL assay in which target cells were transduced with an AAV vector at increasing MOIs and then incu-
bated with HLA-matched effector cells. Teff cells were obtained by restimulating PBMC in vitro with the AAV capsid MHC I peptide VPQYGYLTL alone 
(AAV, black line), with AAV+Tregitope 167 (AAV+hTreg167, dashed black line), with AAV+hTreg167 followed by CD4+ T cell depletion (AAV+hTreg167 
[CD4neg], gray line circles), or with AAV+hTreg167 followed by CD4+ T cell depletion and incubation with 10ng/ml IL-2 overnight (AAV+hTreg167 
[CD4neg + IL-2], gray line triangles). Teff:target ratio 10:1. Results are expressed as % cytotoxicity compared to a max cytotoxicity (cells treated with 
10% SDS) after background subtraction. Experiments shown were repeated at least twice. Error bars represent SEM.
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I peptide complexes which may be located on the surface of the 
Tregitope-specific Treg cells.
In vivo expression of Tregitopes using AAV vectors 
downregulates T cell responses directed against the 
AAV capsid
To test efficacy of modulation of T cell responses directed against 
the AAV capsid in vivo, we used a previously described model of 
adenovirus (Ad) vector-mediated immunization against AAV2, 
which is known to result in generation of a strong CD8+ T cell 
response directed against the capsid antigen.26
To deliver Tregitopes in vivo, we coexpressed Tregitopes (or a 
Scramble control) and the AAV2 capsid protein VP1 separated by 
a PACE/Furin cleavage signal27 under the transcriptional control 
of a CMV promoter (Figure 6a). These were packaged into AAV1 
vectors and given intramuscularly to C57BL/6 mice at a dose of 
2 × 1011 vector genomes (vg)/mouse. Six weeks following vector 
delivery, mice were challenged (intramuscularly) with 1 × 1011 
viral particles of an Ad-AAV2 vector, and animals were sacri-
ficed 9 days later (Figure 6b). Analysis of CD8+ T cell responses 
in splenocytes showed a significant downregulation (P = 0.0428, 
two-tailed unpaired t-test) of IFN-γ responses directed to the 
AAV capsid in animals receiving the AAV-Tregitope vector as 
compared with the controls (Figure 6c,d).
An increase in frequency of CD4+CD25+FoxP3+ T cells was 
detected in spleens of AAV-Tregitope-injected animals (Figure 
6e, P = 0.0256, two-tailed unpaired t-test), whereas a decrease 
in muscle CD4+ and CD8+ T cell infiltrates was observed 
(Supplementary Figure S5a; cells from five animals per group 
were pooled for the analysis). Finally, after Ad-AAV2 immu-
nization, anti-AAV IgG levels were significantly decreased (P = 
0.0031, two-tailed, unpaired t-test) in AAV-Tregitope-injected 
animals (Supplementary Figure S5b). RT Q-PCR confirmed 
transgene expression in muscle following vector delivery in mice 
receiving both the AAV-Tregitope and the AAV scramble vectors 
(Supplementary Figure S6a); similarly, vector genomes were 
detectable in both groups (Supplementary Figure S6b). Despite 
the presence of infiltrates, no loss of vector-transduced fibers was 
noted, a phenomenon previously associated with the apoptosis of 
reactive T cells.28
Although the Tregitope-mediated modulation of T cell 
responses in vivo was only partial, these results suggest that the 
Figure 5 Antigen-specificity of Tregitopes-induced suppression of CTL responses is mediated by MHC I. (a) CTL assay in which target cells were 
loaded with the MHC I epitope VPQYGYLTL from AAV and incubated with HLA-matched AAV-specific Teff alone (AAV, dashed line), or Teff mixed 
at a 1:1 ratio with negatively-selected CD4+ T cells from AAV+hTreg167 restimulated PBMC (AAV+[AAV-hTreg167 CD4+], black line), or Teff mixed 
at a 1:1 ratio with negatively-selected CD4+ T cells from EBV+hTreg167 restimulated PBMC (AAV+[EBV-hTreg167 CD4+], gray line). (b) CTL assay 
as in (a) in which target cells were loaded with the MHC I epitope RPPIFIRRL from EBV and incubated with HLA-matched EBV-specific Teff alone 
(EBV, dashed line), or mixed 1:1 with negatively-isolated CD4+ T cells from EBV+hTreg167 cultures (EBV+[EBV-hTreg167 CD4+], gray line) or with 
negatively-isolated CD4+ T cells from AAV+hTreg167 cultures (EBV+[AAV-hTreg167 CD4+], black line). Teff:target ratio 10:1. Results are expressed 
as % cytotoxicity compared to a max cytotoxicity (cells treated with 10% SDS) after background subtraction. (c) MHC I blockade experiment. Black 
bars: PBMC were restimulated in vitro with AAV+hTreg167 and CD4+ T cells were negatively selected and incubated with increasing amounts of 
soluble AAV-specific TCR. After washing, CD4+ T cells were mixed 1:1 with AAV-specific Teff and added to targets. Grey bar: PBMC restimulated 
with AAV MHC I epitope only, used as positive control (AAV only). White bar: PBMC restimulated with AAV MHC I only mixed 1:1 with CD4+ T cells 
derived from cell restimulated with hTreg167 only, without AAV (hTreg167 only). AAV+AAV-TCR control, CTL in which AAV-only Teff were used the 
CTL assay in the presence of 20 µg/ml of AAV-TCR. Shown is the % cytotoxicity. Error bars represent the standard error of the mean of quadruplicate 
testing. Comparison of results with the AAV-only condition gave the following p values (unpaired, two-tailed t test): AAV-TCR 0 µg/ml P = 0.00262, 1 
µg/ml P = 0.00016, 5 µg/ml P = 0.00112, 20 µg/ml P = 0.03335; hTreg167 only P = 0.86133; AAV+AAV-TCR P < 0.00001. Experiments shown were 
repeated at least twice. Error bars represent SEM.
0
10
20
30
%
 C
yt
ot
ox
ic
ity
40
50
60a
0
0 1 5 20
AAV + AAV
-TCR
hTreg167 only
AAV only
10
20
15
5
25
30
%
 C
yt
ot
ox
ic
ity
c
AAV + [EBV-hTreg167 CD4+]
EBV + [EBV-hTreg167 CD4+]
AAV + [AAV-hTreg167 CD4+]
EBV + [AAV-hTreg167 CD4+]
EBV
AAV
µg/ml AAV peptide
µg/ml soluble
AAV-TCR
AAV + hTreg167
0
0 10 20 30 40 50
µg/ml AAV peptide
0 10 20 30 40 50
10
−10
20
30
%
 C
yt
ot
ox
ic
ity
40
50
70
80
60
b
1732 www.moleculartherapy.org vol. 21 no. 9 sep. 2013
© The American Society of Gene & Cell Therapy
Modulation of CD8+ T cell responses to AAV vectors
proposed approach may be valuable in the modulation of capsid T 
cell immunity in vivo and that further studies, in which the dosing 
of Tregitopes is calibrated to the antigenic stimulus, may effec-
tively modulate anti-AAV immune responses.
DISCUSSION
Immune responses directed against the AAV capsid constitute an 
important obstacle to safe and effective gene transfer in humans.2 
Whereas in some cases, pharmacological immunosuppression has 
proven efficacious in modulating these responses,5 the potential 
limitations of the approach prompted us to explore a more physi-
ological strategy to achieve the goal of sustained gene transfer fol-
lowing in vivo gene delivery with AAV vectors.
Over the past several years, Treg-mediated modulation of 
immune responses has been explored in several models of autoim-
munity, transplant medicine, and gene transfer.29,30 Peptide-mediated 
expansion of Tregs in vivo showed some degree of efficacy in pre-
clinical31 and clinical32 models of autoimmune diseases like lupus.
The work presented here was initiated based on the observa-
tion that in vivo administration of IVIg results in modulation of 
immune responses and is associated with the expansion of regu-
latory T cells (Tregs),33 and that MHC II epitopes found in IgG 
(Tregitopes) have immunomodulatory properties.20,24
Here, we provide direct evidence that Tregitopes can act as 
potent modulators of CD8+ T cell responses against an antigen 
in vitro, and that expression of Tregitopes in vivo is effective in 
reducing T cell activation in response to adenoviral challenge.
We took advantage of an in vitro model of CD8+ T cell 
immunity directed against the AAV capsid,4,8 which overcomes 
the limitations of animal models34–37 and offers the advantage of 
working with effector and target cells that are of human origin 
and for which reagents specific to monitor AAV capsid antigen 
presentation and immunogenicity are well defined.4,7,8 Our data 
with this in vitro system indicate that Tregitopes are highly effec-
tive in modulating MHC I-driven T cell responses via the activa-
tion of a pool of pre-existing CD4+CD25+ T cells, as suggested 
by the following observations: (i) depletion of CD25+ T cells 
prior to Tregitope restimulation completely ablates the immu-
nomodulatory effect of Tregitopes. This result is consistent with 
the studies that show expansion of Tregs in the thymus following 
Figure 6 Expression of Tregitopes in vivo results in modulation of capsid-specific IFN-γ responses. (a) Diagram of the transgene expression cas-
sette used to co-express AAV capsid antigen (AAV2VP1) and Tregitope or Scramble peptides. ITR, inverted terminal repeats; CMV, cytomegalovirus 
enhancer/promoter; RKR, PACE/Furin cleavage sequence; pA, poly-A signal. (b) Experimental design. At day 0, C57BL/6 mice received the Tregitope 
vector or the Scramble control intramuscularly, 2 × 1011 vg/mouse; six weeks later, animals were immunized with an adenoviral vector expressing the 
AAV2 VP1 protein injected intramuscularly, 1 × 1011 vp/mouse. Nine days after Ad immunization animals were sacrificed. (c) Intracellular cytokine 
staining for IFN-γ after AAV peptide restimulation of splenocytes isolated from animals 9 days after adenoviral challenge. After live/dead exclusion, 
cells were gated on lymphocytes, and CD8+ T cells were then analyzed for IFN-γ positivity. (d) Histogram plot of the frequency of CD8+IFN-γ+ T cells 
shown in panels (c) in animals receiving the AAV-Tregitope (T) or AAV-Scramble (S) vectors, the y-axis represents the percent of total lymphocytes that 
are CD8+IFN-γ+; *P = 0.0428. (e) Frequency of CD4+CD25hi cells that are FoxP3+ in splenocytes of animals receiving the AAV-Tregitope (T) or AAV-
Scramble (S) vectors; after live/dead exclusion, cells were gated on lymphocytes, CD4+ T cells, and CD25hi cells were analyzed for FoxP3 expression; 
the y-axis represents the percent of CD4+ T cells that are CD25hiFoxP3+; *P = 0.0256. Shown are individual animals from one of three independent 
experiments. Error bars represent SEM.
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Tregitope administration in vivo;22 (ii) in vitro studies also show 
that CD8+ Teff cells contacted by Tregitope-expanded suppressor 
cells lose their effector function and become anergic, as shown 
in suppression experiments in which negatively-selected puri-
fied CD4+ (Tsupp) and CD8+ (Teff) cells were mixed together, 
resulting in dose-dependent decrease in cytotoxicity; (iii) removal 
of CD4+ T cells and incubation of Teff with IL-2 restored cyto-
toxicity. This is suggestive of a model in which Tregitope-specific 
CD4+CD25hiFoxP3+ suppressor cells are expanded in the pres-
ence of Tregitopes, and inhibit CD8-mediated CTL activity by 
directly contacting the antigen-specific CD8+ Teff via MHC I and 
by interfering with IL-2-mediated signaling, even in the presence 
of IL-2-supplemented restimulation medium. Secretion of immu-
nomodulatory cytokines does not seem to be the main mecha-
nism of modulation of CD8+ T cell activation and function, 
although higher levels of IL-10 are found in cell cultures contain-
ing Tregitopes, whereas MHC I-TCR interaction seems to mediate 
antigen specificity of CD4+CD25+FoxP3+ T cells expanded with 
Tregitopes, at least in vitro. The interaction between suppressor 
and effector T cells results in anergy of Teff cells, which is revers-
ible when additional IL-2 is provided.
The antigen specificity of immunomodulation mediated by 
Tregitopes is a desirable feature of the approach presented here, 
as suppression of immune responses to pathogens would other-
wise constitute an important side effect of this strategy, and is a 
clear advantage over global suppression of immune responses 
with pharmacological agents. Future studies will help assess the 
robustness of antigen specificity and the requirement for cell-to-
cell contact in vivo.
Antigen-specific tolerance via MHC I-TCR interaction has 
been described before in the context of veto cells.38 Since the initial 
description, several studies identified cells with antigen-specific 
MHC-restricted veto properties, including T lymphocytes, NK T 
cells, and dendritic cells. In the veto model, TCR-mediated rec-
ognition of the antigen presented in the context of MHC I by the 
veto cell results in cell death of the effector T cell.39 Furthermore, 
antigen presentation by veto cells has been shown to promote B 
cell tolerance.40 Both the in vitro and in vivo results presented here 
suggest that the veto cell model could be a potential mechanism 
of tolerance induction with Tregitopes; however, it should also be 
noted that MHC I presentation of antigen by CD4+ T cells in our 
model does not result in deletion of reactive CD8+ T cells. Rather, 
CD4+CD25+FoxP3+ T cells expanded with Tregitopes appear to 
act via deprivation of activation signals.41
For our in vivo experiments, we used a model of adenovi-
ral vector-mediated immunization to the AAV capsid antigen.26 
This vaccination model was used to overcome the limitations of 
several animal models proposed to mimic capsid T cell immune 
responses observed in humans34,35,37 and provide a stringent test to 
our strategy. We chose to target the muscle because expression of 
transgenes in this tissue is typically immunogenic42 and to colo-
calize the Tregitope expression and the proinflammatory signal 
deriving from the adenoviral vector. Expression of Tregitopes 
with AAV vectors allowed us to overcome the potential limita-
tions of delivery of peptides in vivo.
The lower efficacy of effector response suppression with 
Tregitopes in vivo compared with in vitro may be the result of the 
stringency of the model. Additional factors that may account for 
the lower efficacy of Tregitope in vivo could include suboptimal 
levels of IL-2,43 or relatively low levels of expression of Tregitopes.
Despite these potential limitations, our data show that it is 
possible to use Tregitopes in vivo to modulate immune responses 
to an antigen, and the delivery of these peptides with AAV vectors 
could represent a tool with a wide range of applications.
Future developments will include the use of AAV serotypes 
with high efficiency of transduction in vivo,44 the expression of 
multiple Tregitopes in a single vector, the co-administration 
of IL-2 at the time of Tregitope expression, or the expression of 
Tregitopes in liver, which per se has tolerogenic properties.45 As 
AAV vectors are nonreplicating, recombinant viruses, the window 
of time in which the capsid antigen is present and immunologi-
cally detectable is limited. Direct engineering of the AAV capsid46 
to carry Tregitopes at the N-terminus of the capsid protein VP2, as 
opposed to expressing them, could be a viable strategy to limit the 
duration of the protolerogenic signal deriving from Tregitopes. 
Finally, the recent development of a mouse model of CD8+ T cell 
immune responses following liver gene transfer,47 in which loss of 
transgene expression and increase in liver enzymes is observed 
like in humans, represents an important asset to the development 
of ad hoc tolerization protocols with Tregitopes.
In the future clinical translation of the approach presented 
here, one potential limitation to the use of Tregitopes is the fact 
that efficacy of suppression with these peptides is dependent on 
the HLA class II haplotype of the subject. Low affinity of Tregitope 
peptides for a subject’s MHC II alleles (represented by the iTEM 
score) result, in fact, in less effective modulation of T cell reac-
tivity. This was well exemplified in the experiments showing only 
partial suppression of CTL activity with hTreg289 and complete 
suppression with hTreg167 due to differences in binding affinity 
to the donor’s MHC II alleles; correlation between the iTEM score 
and hTreg167-mediated suppression of CTLs is also suggestive of 
such correlation. However, the affinity of Tregitopes for several 
MHC II alleles20 and the coexpression of strings composed of 
Tregitopes that bind to multiple HLA could allow administration 
of the same tolerizing vector to most subjects.
An important implication of the study presented here is that 
our strategy could be potentially applied to a variety of diseases. 
AAV vectors per se are among the most efficient vectors for in vivo 
gene transfer,1 they have been administered both systemically and 
locally to humans with an excellent safety profile, and they have 
been shown to promote tolerance rather than immunity against 
the expressed transgenes.45 The availability of a wide range of AAV 
capsid serotypes with different tissue tropism,44 the possibility to 
further direct tropism of AAV vectors to a determined tissue,48 
and the broad range of tissue-specific and/or inducible promot-
ers available constitute a great advantage of the strategy presented 
here over the systemic administration of peptides or immunosup-
pressive drugs.
In conclusion, the work presented here shows that MHC II 
epitopes derived from IgG can be used as tolerizing agents to 
modulate CD8+ T cell responses in vitro and in vivo. The use of 
AAV vectors as delivery vehicles for Tregitopes represents a novel 
strategy to deliver tolerogenic peptides to modulate immune 
responses to viral vectors and other antigens.
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MATERIALS AND METHODS
Peptides. The AAV2 MHC I epitopes VPQYGYLTL and SADNNNSEY, 
restricted to the human HLA-B*0702 and HLA-A*0101 alleles, respec-
tively,4 were obtained from Genemed Synthesis. The AAV2 MHC I 
epitope SNYNKSVNV, restricted to the mouse allele Kb,26 was also 
obtained from Genemed Synthesis; this epitope from the AAV2 cap-
sid is not conserved in the AAV1 capsid. The HLA-B*0702-restricted 
peptide epitopes from EBV (RPPIFIRRL), CMV (TPRVTGGGAM), 
HCV (DPRRRSRNL), and influenza (QPEWFRNVL) were obtained 
from Proimmune. hTreg-167 (PAVLQSSGLYSLSSVVTVPSSSLGTQ), 
hTreg-289 (EEQYNSTYRVVSVLTVLHQDW), the scamble negative 
control peptides Scramble 1 (SPYQSVTSSVLGLLSPVSASVSQTLG), 
Scramble 2 (SSGVQPLLVVYSSLVTSPSASSGLTQ), and Scramble 3 
(SSGSQALVLVYSPSSVLVPTSSTGQL), and the control peptide from 
influenza hemagglutinin (307-319) (PKYVKQNTLKLAT) were synthe-
sized by 21st Century Biochemicals with a 5′ acylation modification and 
an amidylation modification at the 3′ terminus. All peptides were resus-
pended to a concentration of 5 mg/ml. Affinity of the Tregitopes used in 
this study for human class II alleles has been previously discussed.20
Vectors. The AAV serotype 1 vectors used in the study encoded the AAV2 
VP1 capsid protein fused to the Tregitope sequence (AAV-Tregitope) or a 
scrambled version of the Tregitope sequence (AAV-Scramble). A PACE/furin 
cleavage sequence was inserted between the VP1 sequence and the Tregitope/
Scramble sequence to ensure cleavage of the two proteins.27 Expression of 
transgenes was driven by a CMV promoter/enhancer sequence. All AAV 
vectors were administered at a dose of 2 × 1011 vector genomes (vg)/mouse. 
The adenoviral vector expressing the AAV2 VP1 capsid protein (Ad-AAV2) 
was previously described.26 The Ad-AAV2 vector was given at a dose of 
1 × 1011 virus particles (vp)/mouse. All vectors were produced as previously 
described26 and injected intramuscularly (intramuscularly).
Cell lines, peripheral blood mononuclear cells. The human hepatocyte cell 
line HHL5 (carrying the human HLA-A*0101 allele) and the HHL5 cell line 
genetically modified to express the human HLA-B*0702 allele, used as tar-
gets in the CTL assay, were previously described.7,8 Healthy donor PBMCs 
were obtained from Cellular Technologies (Cleveland, OH) and selected 
based on their HLA haplotype; so, they were carrier of the HLA-A*0101 or 
HLA-B*0702 alleles as well as matching the DRB1 alleles previously reported 
to be high-affinity binders of Tregitopes used in the study.20 All human 
specimens were deidentified and handled under a protocol approved by the 
Children’s Hospital of Philadelphia’s Institutional Review Board.
In vitro expansion of T cells. Restimulation of PBMCs in vitro was per-
formed as previously described.4 Briefly, cells were thawed, washed, 
counted, and resuspended at a concentration of 2 × 106 cells/ml in AIM-V 
lymphocyte media (Invitrogen Gibco, Carlsbad, CA) containing 3% 
human serum (Bioreclamation), 1% L-glutamine (Invitrogen Gibco), and 
1% penicillin/streptomycin (Invitrogen Gibco). For each expansion con-
dition, 1 × 106 cells were added to a well in a 24-well plate (BD Falcon). 
1 × 106 of autologous-irradiated PBMC (3000 rad) were also added to each 
well together with 10 ng/ml of human recombinant IL-7 (R&D Systems, 
Minneapolis, MN). According to the experimental conditions for each 
expansion well, peptides were added at a final concentration of 10 µg/ml 
in 5% CO2, 10 ng/well of human IL-2 (Roche, Indianapolis, IN) was added 
to the cell culture and replenished every 48 hours thereafter. Cells were 
divided into new wells as the expansion proceeded, and antigenic stimula-
tion (antigen and feeder cells) was repeated every 7–10 days for up to two 
rounds of restimulation. Expanded CD8+ T cells were characterized after 
each round of stimulation by IFN-γ ELISpot, MHC I pentamer staining, or 
intracellular cytokine staining.
Flow cytometry, intracellular cytokine staining, and polyfunctional anal-
ysis of T cell activation markers. Surface staining and IFN-γ intracellular 
cytokine staining was performed as previously described.4,26 Regulatory T 
cell staining was performed using human or mouse regulatory Treg-staining 
kits (eBioscience, San Diego, CA) containing antibodies for CD4, CD25, 
and FoxP3. For polyfunctional analysis of T cell activation markers, cells 
were washed and counted using an automated cell counter (Invitrogen), 
resuspended at a concentration of 2 × 106 cells/ml, and incubated overnight 
at 37 °C in 5% CO2. The next day, 1 × 106 cells were treated with 1 µg each 
of anti-CD28 and anti-CD49d antibodies (BD Biosciences, Franklin Lakes, 
NJ), and with 10 µl of anti-CD107a antibody (BD Biosciences). Cells were 
then stimulated with 10 µg/ml of peptide, 10 µg/ml of Staphylococcal entero-
toxin B (SEB, Sigma, St Louis, MO), or left untreated as a negative control 
for 1 hour at 37 °C, 5% CO2 prior to adding 10 µg of brefeldin A (Sigma) and 
0.7 µl of monensin (GolgiStop, BD Biosciences). After an additional 5-hour 
incubation, cells were washed in PBS and stained for the surface markers 
CD3, CD4, CD8, CD14, CD16, and CD19 (BD Biosciences or Caltag). Cells 
were then washed once with PBS 2% FBS, and then fixed and permeabilized 
with 200 µl of Cytofix/Cytoperm solution (BD Biosciences). Intracellular 
staining for cytokines was performed at room temperature using antibod-
ies against IFN-γ, TNF-α, and IL-2 (BD Biosciences). Cells were fixed with 
2% paraformaldehyde prior to acquisition on a FACS Canto II flow cytom-
eter; analysis was conducted using FACSDiva (BD Biosciences) and Flowjo 
(Treestar) software.
CTL assay. The CTL assay was performed as previously described.7,8 Briefly, 
lactate dehydrogenase (LDH) release following CTL-mediated target lysis 
was measured with the CytoTox 96 Non Radioactive Cytotoxicity Assay 
(Promega, Madison, WI). Five thousand HHL5 target cells were plated in 
each well of a Microtest Primaria flat-bottom 96-well plate (BD Falcon) in 
DMEM containing no serum. Targets were either transduced at a range of 
multiplicity of infections (see Results) with an AAV vector, or loaded with 
MHC class I epitopes at indicated concentrations (see Results) and incu-
bated for 18 hours at 37 °C, 5% CO2. Teff cells were added at a Teff:target 
ratio of 10:1 unless otherwise noted, and cell lysis was measured after four 
hours of incubation.
Cytokine profiling. Conditioned medium was sampled immediately 
after cells were plated (day 0) and then twice daily on day 4, 8, 13, and 18 
during in vitro restimulation and prior to feeding cells with IL-2. Media 
withdrawn for sampling was replaced with an equal volume of medium. 
Cytokine analysis was performed by ELISA. The multiplex assay was per-
formed using a Milliplex MAP Human Cytokine/Chemokine Pre-mixed 
14-plex kit (Millipore, Billercia, MA) on a Luminex 200 instrument and 
analyzed with xPONENT software (Luminex, Austin, TX). Analytes and 
individual lower limit of detection were as follows: granular-macrophage 
colony stimulating factor (GM-CSF): 2.75 pg/ml; IFN-γ: 2.97 pg/ml; IL-1 
β: 1.64 pg/ml; IL-2: 2.51 pg/ml; IL-4: 2.94 pg/ml; IL-5: 3.05 pg/ml; IL-6: 
3.01 pg/ml; IL-7: 2.95 pg/ml; IL-8: 3.01 pg/ml; IL-10: 0.41 pg/ml; IL-12 
(p70): 2.99 pg/ml; IL-13: 1.31 pg/ml; monocyte chemotactic protein 1 
(MCP-1): 2.97 pg/ml; and TNF-α: 3.01 pg/ml. The multiplex assay did not 
show variation in any of the cytokines or chemokines tested (not shown).
Isolation and depletion of T cell subsets. For studies involving the selec-
tion or depletion of subpopulations of T cells, antibody-coated magnetic 
bead separation was performed to negatively select for untouched CD4+ 
and CD8+ T cells, or to deplete CD25+, CD4+, or CD8+ T cell populations 
(Invitrogen Dynal) according to the manufacturer’s protocols. Isolated 
cell populations were either used directly in CTL assays or cultured until 
assayed. Surface staining followed by flow cytometry was used to confirm 
the success of cell separation or depletion.
Assay for contact-dependent inhibition of cytotoxicity. PBMCs were sep-
arated into CD4-depleted and CD8-depleted fractions and then cultured 
in separate chambers of a 0.4 µM Transwell permeable support (Corning). 
Cells were restimulated for 2 weeks in the presence of the AAV MHC I 
peptide VPQYGYLTL and hTreg167 as described above. After restimula-
tion, cells were harvested from the CD4-depleted chamber of the transwell 
(containing the CD8+ fraction of PBMCs) and tested in a CTL assay.
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MHC I blockade experiment. To demonstrate that antigen specific-
ity of Tregitope-mediated CTL suppression is dependent on MHC I, we 
performed a MHC I blockade. We previously described the develop-
ment of soluble TCR monomers specific for the HLA-B*0702 epitope 
VPQYGYLTL.4 This TCR is HLA- and epitope-specific and can mediate 
complete blockage of MHC I.8 In this experiment, PBMCs from the same 
donor were restimulated in vitro with AAV+hTreg167, AAV, or hTreg167.
Cells stimulated with AAV+hTreg167 were used to negatively select 
CD4+ T cells using Dynabeads (Invitrogen Dynal). These cells were 
then incubated with 0, 1, 5, or 20 µg/ml of soluble TCR monomers at 
room temperature in PBS with 1% BSA. After washing twice in DMEM 
(Gibco, Carlsbad, CA), cells were mixed 1:1 with Teff derived from AAV-
restimulated PBMCs and used in a CTL assay.
As a control, Teff derived from AAV-restimulated PBMCs (in the 
absence of Tregitope) were used (Figure 5C, AAV only).
One additional control consisted of CD4+ T cells derived from 
PBMCs restimulated with hTreg167 only mixed at a 1:1 ratio with Teff 
derived from PBMC restimulated with AAV antigen only (Figure 5C, 
hTreg167 only). In this control, suppressor cells were never exposed to the 
MHC I epitope from AAV.
Finally, a third control consisted in the addition of soluble TCR 
monomers to the CTL assay in which effector cells were restimulated with 
AAV peptide only.
Animal studies. All mouse experiments were repeated at least twice, 
conducted using 8- to 10-week-old male C57BL/6 mice (Charles River 
Laboratories, Wilmington, MA), and were approved by the Children’s 
Hospital of Philadelphia Institutional Animal Care and Use Committee. 
Animals received the vectors intramuscularly via direct injection into 
both hind limbs. Blood samples were collected into heparinized capillary 
tubes (Fisher Scientific, Waltham, MA) for antibody analysis as previously 
described;45 spleens and lymph nodes were collected and briefly stored in 
cold medium until processed for lymphocyte isolation. Muscle samples 
were snap-frozen in liquid nitrogen for RNA extraction. For cell extrac-
tion, muscle samples were collected in cold Hank’s balanced salt solution 
(HBSS, Invitrogen Gibco) containing 0.05% of proteinase K (Pronase, 
Invitrogen Gibco), homogenized on a gentleMACS Dissociator (Miltenyi 
Biotec, Bergisch Gladbach, Germany), digested for 1 hour at 37 °C, then 
further homogenized, filtered through a 70 µm cell strainer, and washed 
twice in RPMI 1640 medium (Invitrogen Gibco).
Quantitative real-time PCR for transgene expression and vec-
tor gene copy number. RNA was extracted from snap-frozen mus-
cle using TRIzol/chloroform and additional purification performed 
with RNEasy columns (QIAGEN). cDNAs were generated using the 
High-Capacity cDNA Reverse Transcription Kit with RNase Inhibitor 
(Applied Biosystems, Foster City, CA). Taqman Universal Master 
Mix II (Applied Biosystems) was used for quantitative real-time PCR. 
PrimeTime Standard qPCR Assays were ordered from Integrated 
DNA Technologies. For AAV2 VP1 detection, the following reagents 
were used: forward primer: 5′-GACATTTTCACCCCTCTCCC-3′; 
reverse primer: 5′-CAAACTTTGCCGCACTGAAG-3′; and probe 
sequence: 5′-/56-FAM/ACACCCTCC/ZEN/TCCACAGATTCTCATCA/ 
3IABkFQ/-3′. GAPDH was used as an internal control: forward primer: 
5′-AATGGTGAAGGTCGGTGTG-3′; reverse primer: 5′-GTGGAGTCA 
TACTGGAACATGTAG-3′; and probe 5′-/56-FAM/TGCAAATGG/ZEN/
CAGCCCTGGTG/3IABkFQ/-3′. The same set of primers and probe 
were used to determine vector genome copy number on genomic DNA 
extracted from injected muscle. The assays were run on a Mastercycler 
Realplex2 (Eppendorf, Hauppauge, NY).
Bioinformatics and statistical analysis. Tregitope-binding scores (iTEM) 
were obtained from EpiVax (EpiVax, Providence, RI) using the EpiMatrix 
and ClustiMer epitope-mapping algorithms as previously described.20,25,49 
Unpaired t-test was used to compare means across experimental groups, 
two-way ANOVA was used to compare levels of cytokines secreted in 
PBMC cultures. Linear regression was used to analyze the relationship 
between iTEM score and inhibition of CTL activity. Statistical analysis was 
performed using GraphPad (GraphPad Software, La Jolla, CA); P values 
<0.05 were considered significant.
SUPPLEMENTARY MATERIAL
Figure S1. Defining an experimental design for the in vitro testing of 
Tregitopes efficacy.
Figure S2. The binding score of Tregitopes for MHC II shows a rough 
correlation with the inhibition of CTL activity
Figure S3. Both CD4+ and CD8+ T cells proliferate in vitro in the 
presence of Tregitopes.
Figure S4. In vitro restimulation of PBMCs with Tregitopes leads to 
an antiinflammatory cytokine response in the tissue culture media.
Figure S5. Expression of Tregitopes in vivo is associated with reduced 
T cell infltrates in muscle and lower anti-AAV antibody titers.
Figure S6. After AAV vector delivery in vivo, transgene expression 
and vector genome copy number can be detected in injected muscle.
ACkNOwLEDGMENTS
This work was supported by the Center for Cellular and Molecular 
Therapeutics at the Children’s Hospital of Philadelphia. F. M. is sup-
ported by the European Union Marie Curie Career Integration Grant 
number 333628. The authors gratefully acknowledge Drs. K. A. High, 
R. W. Herzog, and J. M. Davoust for the critical discussion of the data. 
L.P.C. and A.S.D. are employees of EpiVax, Inc., the company that 
holds patents on the Tregitope technology. All other authors declare 
no conflict of interest.
REFERENCES
1. Mingozzi, F and High, KA (2011). Therapeutic in vivo gene transfer for genetic disease 
using AAV: progress and challenges. Nat Rev Genet 12: 341–355.
2. Mingozzi, F and High, KA (2011). Immune responses to AAV in clinical trials. Curr 
Gene Ther 11: 321–330.
3. Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ et al. (2006). 
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations 
imposed by the host immune response. Nat Med 12: 342–347.
4. Mingozzi, F, Maus, MV, Hui, DJ, Sabatino, DE, Murphy, SL, Rasko, JE et al. (2007). 
CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 13: 
419–422.
5. Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC et 
al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. 
N Engl J Med 365: 2357–2365.
6. Muzyczka, N, and Berns, KI (2001). Parvoviridae: the viruses and their replication. 
Lippincott, Williams and Wilkins: Philadelphia.
7. Finn, JD (2010). Proteasome inhibitors decrease AAV2 capsid derived peptide epitope 
presentation on MHC class I following transduction. Mol Ther 18: 135–142.
8. Pien, GC, Basner-Tschakarjan, E, Hui, DJ, Mentlik, AN, Finn, JD, Hasbrouck, NC et al. 
(2009). Capsid antigen presentation flags human hepatocytes for destruction after 
transduction by adeno-associated viral vectors. J Clin Invest 119: 1688–1695.
9. Zhong, L, Li, B, Mah, CS, Govindasamy, L, Agbandje-McKenna, M, Cooper, M et 
al. (2008). Next generation of adeno-associated virus 2 vectors: point mutations in 
tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 
105: 7827–7832.
10. Calcedo, R, Morizono, H, Wang, L, McCarter, R, He, J, Jones, D et al. (2011). Adeno-
associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine 
Immunol 18: 1586–1588.
11. Li, C (2011). Neutralizing antibodies against adeno-associated virus examined 
prospectively in pediatric patients with hemophilia. Gene Ther 18: 288–294.
12. Veron, P, Leborgne, C, Monteilhet, V, Boutin, S, Martin, S, Moullier, P et al. (2012). 
Humoral and cellular capsid-specific immune responses to adeno-associated virus type 
1 in randomized healthy donors. J Immunol 188: 6418–6424.
13. Jiang, H, Couto, LB, Patarroyo-White, S, Liu, T, Nagy, D, Vargas, JA et al. (2006). 
Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-
directed gene transfer in rhesus macaques and implications for human gene therapy. 
Blood 108: 3321–3328.
14. Mingozzi, F, Meulenberg, JJ, Hui, DJ, Basner-Tschakarjan, E, Hasbrouck, NC, 
Edmonson, SA et al. (2009). AAV-1-mediated gene transfer to skeletal muscle in 
humans results in dose-dependent activation of capsid-specific T cells. Blood 114: 
2077–2086.
15. Peng, B, Ye, P, Rawlings, DJ, Ochs, HD and Miao, CH (2009). Anti-CD3 antibodies 
modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII 
plasmid-mediated gene therapy. Blood 114: 4373–4382.
16. Safinia, N, Leech, J, Hernandez-Fuentes, M, Lechler, R and Lombardi, G (2013). 
Promoting transplantation tolerance; adoptive regulatory T cell therapy. Clin Exp 
Immunol 172: 158–168.
1736 www.moleculartherapy.org vol. 21 no. 9 sep. 2013
© The American Society of Gene & Cell Therapy
Modulation of CD8+ T cell responses to AAV vectors
17. Battaglia, M and Roncarolo, MG (2011). Immune intervention with T regulatory cells: 
past lessons and future perspectives for type 1 diabetes. Semin Immunol 23: 182–194.
18. Vignali, DA, Collison, LW and Workman, CJ (2008). How regulatory T cells work. Nat 
Rev Immunol 8: 523–532.
19. Shevach, EM (2009). Mechanisms of foxp3+ T regulatory cell-mediated suppression. 
Immunity 30: 636–645.
20. De Groot, AS, Moise, L, McMurry, JA, Wambre, E, Van Overtvelt, L, Moingeon, 
P et al. (2008). Activation of natural regulatory T cells by IgG Fc-derived peptide 
“Tregitopes”. Blood 112: 3303–3311.
21. Cousens, LP, Mingozzi, F, van der Marel, S, Su, Y, Garman, R, Ferreira, V et al. (2012). 
Teaching tolerance: New approaches to enzyme replacement therapy for Pompe 
disease. Hum Vaccin Immunother 8: 1459–1464.
22. van der Marel, S, Majowicz, A, Kwikkers, K, van Logtenstein, R, te Velde, AA, De 
Groot, AS et al. (2012). Adeno-associated virus mediated delivery of Tregitope 167 
ameliorates experimental colitis. World J Gastroenterol 18: 4288–4299.
23. Cousens, LP, Najafian, N, Mingozzi, F, Elyaman, W, Mazer, B, Moise, L et al. (2013). 
In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising 
new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol 33 
Suppl 1: S43–S49.
24. Cousens, LP, Najafian, N, Mingozzi, F, Elyaman, W, Mazer, B, Moise, L et al. (2013). 
In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising 
new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol 33 
Suppl 1: S43–S49.
25. Cohen, T, Moise, L, Ardito, M, Martin, W and De Groot, AS (2010). A method for 
individualizing the prediction of immunogenicity of protein vaccines and biologic 
therapeutics: individualized T cell epitope measure (iTEM). J Biomed Biotechnol 
2010 (doi:10.1155/2010/961752).
26. Sabatino, DE, Mingozzi, F, Hui, DJ, Chen, H, Colosi, P, Ertl, HC et al. (2005). 
Identification of mouse AAV capsid-specific CD8+ T cell epitopes. Mol Ther 12: 
1023–1033.
27. Margaritis, P, Arruda, VR, Aljamali, M, Camire, RM, Schlachterman, A and High, 
KA (2004). Novel therapeutic approach for hemophilia using gene delivery of an 
engineered secreted activated Factor VII. J Clin Invest 113: 1025–1031.
28. Velazquez, VM, Bowen, DG and Walker, CM (2009). Silencing of T lymphocytes by 
antigen-driven programmed death in recombinant adeno-associated virus vector-
mediated gene therapy. Blood 113: 538–545.
29. Tang, Q, Bluestone, JA and Kang, SM (2012). CD4(+)Foxp3(+) regulatory T cell 
therapy in transplantation. J Mol Cell Biol 4: 11–21.
30. Gross, DA, Leboeuf, M, Gjata, B, Danos, O and Davoust, J (2003). CD4+CD25+ 
regulatory T cells inhibit immune-mediated transgene rejection. Blood 102: 4326–
4328.
31. Amarilyo, G, Hahn, B and La Cava, A (2012). Preclinical studies with synthetic 
peptides in systemic lupus erythematosus. Front Biosci 17: 1940–1947.
32. Sthoeger, ZM, Sharabi, A, Molad, Y, Asher, I, Zinger, H, Dayan, M et al. (2009). 
Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): 
immunomodulation of gene expression. J Autoimmun 33: 77–82.
33. Ephrem, A, Chamat, S, Miquel, C, Fisson, S, Mouthon, L, Caligiuri, G et al. (2008). 
Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a 
critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111: 
715–722.
34. Li, C, Hirsch, M, Asokan, A, Zeithaml, B, Ma, H, Kafri, T et al. (2007). Adeno-
associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only 
vector-transduced cells coexpressing the AAV2 capsid in vivo. J Virol 81: 7540–7547.
35. Li, H, Murphy, SL, Giles-Davis, W, Edmonson, S, Xiang, Z, Li, Y et al. (2007). Pre-
existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced 
hepatocytes. Mol Ther 15: 792–800.
36. Li, H, Tuyishime, S, Wu, TL, Giles-Davis, W, Zhou, D, Xiao, W et al. (2011). Adeno-
associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific 
CD8+ T cells in mice. Mol Ther 19: 536–546.
37. Wang, L, Figueredo, J, Calcedo, R, Lin, J and Wilson, JM (2007). Cross-presentation 
of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not 
render hepatocytes effective cytolytic targets. Hum Gene Ther 18: 185–194.
38. Miller, RG (1980). An immunological suppressor cell inactivating cytotoxic 
T-lymphocyte precursor cells recognizing it. Nature 287: 544–546.
39. Reich-Zeliger, S, Eidelstein, Y, Hagin, D, Antebi, YE, Seger, R and Reisner, Y (2010). 
Deletion of alloreactive T cells by veto cytotoxic T lymphocytes is mediated through 
extracellular signal-regulated kinase phosphorylation. Transplantation 90: 380–386.
40. Nguyen, P and Geiger, TL (2010). Induction of B-cell immune tolerance by antigen-
modified cytotoxic T lymphocytes. Transplantation 89: 667–676.
41. Yamaguchi, T, Wing, JB and Sakaguchi, S (2011). Two modes of immune suppression 
by Foxp3(+) regulatory T cells under inflammatory or non-inflammatory conditions. 
Semin Immunol 23: 424–430.
42. Wang, L, Cao, O, Swalm, B, Dobrzynski, E, Mingozzi, F and Herzog, RW (2005). 
Major role of local immune responses in antibody formation to factor IX in AAV gene 
transfer. Gene Ther 12: 1453–1464.
43. Saadoun, D, Rosenzwajg, M, Joly, F, Six, A, Carrat, F, Thibault, V et al. (2011). 
Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl 
J Med 365: 2067–2077.
44. Gao, GP, Alvira, MR, Wang, L, Calcedo, R, Johnston, J and Wilson, JM (2002). Novel 
adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. 
Proc Natl Acad Sci USA 99: 11854–11859.
45. Mingozzi, F, Liu, YL, Dobrzynski, E, Kaufhold, A, Liu, JH, Wang, Y et al. (2003). 
Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic 
gene transfer. J Clin Invest 111: 1347–1356.
46. Warrington, KH Jr, Gorbatyuk, OS, Harrison, JK, Opie, SR, Zolotukhin, S and 
Muzyczka, N (2004). Adeno-associated virus type 2 VP2 capsid protein is nonessential 
and can tolerate large peptide insertions at its N terminus. J Virol 78: 6595–6609.
47. Martino, AT, Basner-Tschakarjan, E, Markusic, DM, Finn, JD, Hinderer, C, Zhou, S et al. 
(2013). Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes 
by capsid-specific CD8+ T cells. Blood 121: 2224–2233.
48. Chen, YH, Chang, M and Davidson, BL (2009). Molecular signatures of disease 
brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med 15: 
1215–1218.
49. Schanen, BC, De Groot, AS, Moise, L, Ardito, M, McClaine, E, Martin, W et al. (2011). 
Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4(+) T 
cells against the swine-origin H1N1 influenza virus. Vaccine 29: 3299–3309.
This work is licensed under a Creative 
Commons Attribution-NonCommercial-No 
Derivative Works 3.0 License. To view a copy of this license, 
visit http://creativecommons.org/licenses/by-nc-nd/3.0/
Molecular Therapy vol. 21 no. 9 sep. 2013 1737
